Table 6.

The adjusted hazard ratios with 95% confidence intervals of drug discontinuation associated with variables in ETN and ADA users during all treatment periods

Variable	Model 1	Model 2	Model 3
	All (n=4,592)	ETN (n=2,609)	ADA (n=1,983)
ADA vs ETN	1.06 (0.98–1.16)	–	–
Female	0.93 (0.83–1.03)	1.06 (0.92–1.23)	1.06 (0.90–1.25)
RA disease duration, >3 years	1.01 (0.92–1.11)	0.95 (0.84–1.07)	1.07 (0.92–1.24)
Age at drug initiation, ≥65 years	1.20 (1.09–1.32)	1.143 (1.006–1.299)	1.30 (1.12–1.50)
Within 1 year before anti-TNF use
CCI, ≥2	1.01 (0.93–1.10)	0.97 (0.86–1.08)	1.08 (0.94–1.23)
MTX, >10 mg/wk	0.90 (0.83–0.99)	0.89 (0.80–1.08)	0.90 (0.78–1.04)
Leflunomide	1.15 (1.03–1.28)	1.06 (0.92–1.23)	1.25 (1.07–1.48)
Salazopyrin	1.24 (1.10–1.40)	1.28 (1.09–1.51)	1.21 (1.01–1.45)
Hydroxychloroquine	1.26 (1.10–1.43)	1.54 (1.28–1.84)	0.98 (0.81–1.18)
NSAID	2.46 (1.55–3.90)	1.60 (0.88–2.92)	3.41 (1.64–7.08)
Pd, >5 mg/d	0.88 (0.80–0.97)	0.82 (0.72–0.92)	0.99 (0.85–1.15)
Comedication
MTX, >10 mg/wk	0.83 (0.76–0.91)	0.75 (0.66–0.85)	0.95 (0.83–1.10)
Leflunomide	0.85 (0.76–0.96)	0.86 (0.73–1.02)	0.86 (0.72–1.02)
Salazopyrin	0.82 (0.74–0.92)	0.86 (0.75–0.99)	0.77 (0.66–0.91)
Hydroxychloroquine	0.88 (0.81–0.99)	0.85 (0.74–0.97)	0.93 (0.80–1.09)
NSAID	0.22 (0.18–0.27)	0.16 (0.12–0.20)	0.30 (0.22–0.42)
Pd, >5 mg/d	1.86 (1.68–2.05)	1.85 (1.61–2.11)	1.86 (1.60–2.16)

Abbreviations: ADA, adalimumab; ETN, etanercept; RA, rheumatoid arthritis; TNF, tumor necrosis factor; CCI, Charlson comorbidity index; MTX, methotrexate; NSAID, nonsteroid anti-inflammatory drug; Pd, prednisolone.